Literature DB >> 16956313

Orlistat: a review of its use in the management of obesity.

Sheridan Henness1, Caroline M Perry.   

Abstract

Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data have shown that orlistat is also effective as a component of weight management strategies in obese adolescents. In addition to its well established efficacy in achieving modest weight loss, orlistat has been shown to improve glycaemic parameters in obese adults with type 2 diabetes mellitus as well as some features of the metabolic syndrome. Orlistat is generally well tolerated. Thus, orlistat is an option for the treatment of obese patients with or without type 2 diabetes and also has a role in the management of obese patients with the metabolic syndrome, associated comorbidities or concomitant disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956313     DOI: 10.2165/00003495-200666120-00012

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  97 in total

1.  Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents.

Authors:  David Maahs; Daniela Gonzalez de Serna; Ronette L Kolotkin; Shawn Ralston; Jeffrey Sandate; Clifford Qualls; David S Schade
Journal:  Endocr Pract       Date:  2006 Jan-Feb       Impact factor: 3.443

2.  The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers.

Authors:  J Zhi; A T Melia; S G Koss-Twardy; B Min; R Guerciolini; N L Freundlich; G Milla; I H Patel
Journal:  J Clin Pharmacol       Date:  1995-05       Impact factor: 3.126

3.  A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.

Authors:  Mark Lamotte; Lieven Annemans; Aurelia Lefever; Myriam Nechelput; Johan Masure
Journal:  Diabetes Care       Date:  2002-02       Impact factor: 19.112

4.  Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns.

Authors:  L Karhunen; A Franssila-Kallunki; P Rissanen; R Valve; M Kolehmainen; A Rissanen; M Uusitupa
Journal:  Int J Obes Relat Metab Disord       Date:  2000-12

5.  The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Authors:  J Zhi; A T Melia; R Guerciolini; S G Koss-Twardy; S M Passe; A Rakhit; J A Sadowski
Journal:  J Clin Pharmacol       Date:  1996-07       Impact factor: 3.126

6.  The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers.

Authors:  A T Melia; S G Koss-Twardy; J Zhi
Journal:  J Clin Pharmacol       Date:  1996-07       Impact factor: 3.126

7.  Effects of orlistat on obesity-related diseases - a six-month randomized trial.

Authors:  B Guy-Grand; P Drouin; E Eschwège; H Gin; J-M Joubert; P Valensi
Journal:  Diabetes Obes Metab       Date:  2004-09       Impact factor: 6.577

8.  Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.

Authors:  P Koskinen; M Mänttäri; V Manninen; J K Huttunen; O P Heinonen; M H Frick
Journal:  Diabetes Care       Date:  1992-07       Impact factor: 19.112

9.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Authors:  M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

10.  Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions.

Authors:  Jennifer R McDuffie; Karim A Calis; Gabriel I Uwaifo; Nancy G Sebring; Erica M Fallon; Teresa E Frazer; S Van Hubbard; Jack A Yanovski
Journal:  J Pediatr Endocrinol Metab       Date:  2004-03       Impact factor: 1.634

View more
  19 in total

Review 1.  Enzymatic pathways that regulate endocannabinoid signaling in the nervous system.

Authors:  Kay Ahn; Michele K McKinney; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2008-04-23       Impact factor: 60.622

2.  Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the Treatment of Obesity: A Randomized Dose-Finding Study.

Authors:  Hans Hauner; Ljiljana Hastreiter; Dieter Werdier; Annette Chen-Stute; Jürgen Scholze; Matthias Blüher
Journal:  Obes Facts       Date:  2017-09-06       Impact factor: 3.942

3.  Development and optimization of piperidyl-1,2,3-triazole ureas as selective chemical probes of endocannabinoid biosynthesis.

Authors:  Ku-Lung Hsu; Katsunori Tsuboi; Landon R Whitby; Anna E Speers; Holly Pugh; Jordon Inloes; Benjamin F Cravatt
Journal:  J Med Chem       Date:  2013-10-23       Impact factor: 7.446

4.  Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening.

Authors:  Daniel A Bachovchin; Tianyang Ji; Weiwei Li; Gabriel M Simon; Jacqueline L Blankman; Alexander Adibekian; Heather Hoover; Sherry Niessen; Benjamin F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-17       Impact factor: 11.205

5.  Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study.

Authors:  Russell M Viner; Yingfen Hsia; Antje Neubert; Ian C K Wong
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 6.  Obesity management in adults with CKD.

Authors:  Holly Kramer; Katherine R Tuttle; David Leehey; Amy Luke; Ramon Durazo-Arvizu; David Shoham; Richard Cooper; Srinvisan Beddhu
Journal:  Am J Kidney Dis       Date:  2009-01       Impact factor: 8.860

7.  Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling.

Authors:  Heather S Hoover; Jacqueline L Blankman; Sherry Niessen; Benjamin F Cravatt
Journal:  Bioorg Med Chem Lett       Date:  2008-07-02       Impact factor: 2.823

8.  Activity based protein profiling to detect serine hydrolase alterations in virus infected cells.

Authors:  Md Shahiduzzaman; Kevin M Coombs
Journal:  Front Microbiol       Date:  2012-08-22       Impact factor: 5.640

9.  Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors.

Authors:  Alexander Adibekian; Brent R Martin; Chu Wang; Ku-Lung Hsu; Daniel A Bachovchin; Sherry Niessen; Heather Hoover; Benjamin F Cravatt
Journal:  Nat Chem Biol       Date:  2011-05-15       Impact factor: 15.040

Review 10.  The risk of cardiovascular complications with current obesity drugs.

Authors:  Ariana M Chao; Thomas A Wadden; Robert I Berkowitz; Kerry Quigley; Frank Silvestry
Journal:  Expert Opin Drug Saf       Date:  2020-09-09       Impact factor: 4.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.